Galderma receives Investment Bank Analyst Rating Update
- Investing.com
Pro
- English (USA)
- English (India)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Galderma Group AG (GALD)
Assess today's live Galderma Group AG (GALD) share price, performance and insights using our live Switzerland: GALD stock exchange data.
Analyse the historical data and Galderma Group AG share price performance charts on this page. Our technical summary section provides analysis on Galderma share price buy/sell indicators using real-time data (or discuss the Galderma (GALD) stock price today with other investors in the Galderma SIX share price and sentiment chat forum).
Use the dropdown to select a relevant stock exchange for the current SIX GALD share price (ISIN: CH1335392721) to enhance your trading decisions with our free investment tools and resources.
What Is the Galderma Group AG Share Price Today?
The Galderma share price today is 155.60.
What Is the Stock Symbol for Galderma Group AG
The stock symbol (or 'ticker') for Galderma Group AG is "GALD."
What Stock Exchange Does Galderma Group AG Trade On?
Galderma Group AG is listed and trades on the Switzerland stock exchange.
Is Galderma Group AG a Good Stock to Buy?
Determining whether Galderma Group AG—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, investors can sign up to InvestingPro, where they can assess share price, fair value and other essential metrics.
Analyse the historical data and Galderma Group AG share price performance charts on this page. Our technical summary section provides analysis on Galderma share price buy/sell indicators using real-time data (or discuss the Galderma (GALD) stock price today with other investors in the Galderma SIX share price and sentiment chat forum).
Use the dropdown to select a relevant stock exchange for the current SIX GALD share price (ISIN: CH1335392721) to enhance your trading decisions with our free investment tools and resources.
What Is the Galderma Group AG Share Price Today?
The Galderma share price today is 155.60.
What Is the Stock Symbol for Galderma Group AG
The stock symbol (or 'ticker') for Galderma Group AG is "GALD."
What Stock Exchange Does Galderma Group AG Trade On?
Galderma Group AG is listed and trades on the Switzerland stock exchange.
Is Galderma Group AG a Good Stock to Buy?
Determining whether Galderma Group AG—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, investors can sign up to InvestingPro, where they can assess share price, fair value and other essential metrics.
Currency in CHF
155.60
-0.30(-0.19%)
Delayed Data·
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
154.80
160.80
52 wk Range
72.70
170.10
GALD is included in our AI-picked strategies. See how they work
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
154.80160.80
52 wk Range
72.70170.10
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
(0.10%)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Book Value / Share
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
(0.10%)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Book Value / Share
GALD Scorecard
Company’s Health
Assesses a company's financial position by analysing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Strong Buy
Price Target
177.11
Upside
+13.82%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Significant return over the last week
- Galderma receives Investment Bank Analyst Rating Update
- Investing.com
Pro
- Galderma receives Investment Bank Analyst Rating Update
- Investing.com
Pro - Galderma receives Investment Bank Analyst Rating Update
- Investing.com
Pro - Galderma receives Investment Bank Analyst Rating Update
- Investing.com
Pro
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Buy
Technical Indicators
Strong Buy
Moving Averages
Buy
Galderma Group AG operates as a dermatology company worldwide. The company delivers a science-based portfolio of brands and services for the dermatology market, including injectable aesthetics, dermatological skincare, and therapeutic dermatology. Its portfolio of flagship brands includes Azzalure, ALLUZIENCE, Dysport, Restylane, Restylane Skinboosters, Sculptra, Cetaphil, ALASTIN, Soolantra, Epiduo, Epiduo Forte, Differin, AKLIEF, Oracea, Metvix, NEMLUVIO, Relfydess, Benzac, and Loceryl in therapeutic dermatology. The company was founded in 1981 and is headquartered in Zug, Switzerland.
Galderma Group AG Earnings Call Summary for Q4/2025
- Galderma posted record Q4 2025 net sales of $5.2B, up 17.7% YoY at constant currency; stock surged 6.28% to $153.90 following announcement.
- Core EPS jumped 76.7% to $3.69 driven by EBITDA growth and lower financing costs; company proposed 230% dividend increase for shareholders.
- Core EBITDA reached $1.211B, up 18.9% YoY with margin expansion to 23.3%; gross profit margin stood at 69% reflecting strong pricing power.
- Nemolizumab peak sales guidance raised to $4B; FY2026 revenue projected at $6.151B with EPS forecast of $4.62, implying continued growth momentum.
- CEO cited integrated dermatology platform strength; key risks include competitive pressures, regulatory approval delays, and economic headwinds.
Last Updated: 05/03/2026, 14:50
Read Full TranscriptCompare GALD to Peers and Sector
Metrics to compare | GALD | Sector Sector - Average of metrics from a broad group of related Consumer Non-Cyclicals sector companies | Relationship RelationshipGALDPeersSector | |
|---|---|---|---|---|
P/E Ratio | 123.8x | 23.0x | −0.5x | |
PEG Ratio | 0.05 | 0.00 | 0.00 | |
Price/Book | 6.1x | 2.1x | 2.6x | |
Price / LTM Sales | 10.0x | 4.1x | 3.2x | |
Upside (Analyst Target) | 16.8% | 22.7% | 51.4% | |
Fair Value Upside | Unlock | 4.8% | 7.1% | Unlock |
Analyst Ratings
11 Buy
3 Hold
1 Sell
Ratings:
15 analysts
Overall Consensus
Buy
Analysts 12-Month Price Target:
Average 177.11
(+13.82% Upside)
Earnings
Latest Release
Jul 24, 2025
EPS / Forecast
0.82 / --
Revenue / Forecast
2.47B / 1.098B
People Also Watch
FAQ
What Is the Galderma (GALD) Share Price Today?
The Galderma stock price today is 155.60 CHF.
What Stock Exchange Does Galderma (GALD) Trade On?
Galderma is listed and trades on the Switzerland Stock Exchange.
What Is the Ticker (Stock Symbol) for Galderma?
The stock symbol (also called a 'ticker') for Galderma is "GALD."
Does Galderma Pay Dividends? What’s The Current GALD Dividend Yield?
Yes, GALD Pays Dividends to its Shareholders. The current Galderma dividend yield is 0.1%.
What Is the Current Galderma Market Cap?
As of today, Galderma market cap is 36.57B CHF.
What Is Galderma's (GALD) Earnings Per Share (TTM)?
The Galderma EPS is currently 2.60 (Trailing Twelve Months).
Is GALD a Buy or Sell From a Technical Analyst Perspective?
Based on today's Galderma moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.
How Many Times Has Galderma Stock Split?
Galderma has split 0 times. (See the GALD stock split history page for full effective split date and price information.)
How Many Employees Does Galderma Have?
Galderma has 7676 employees.
What is the current trading status of Galderma (GALD)?
As of 10/03/2026, Galderma (GALD) is trading at a price of 155.60 CHF, with a previous close of 155.90 CHF. The stock has fluctuated within a day range of 154.80 CHF to 160.80 CHF, while its 52-week range spans from 72.70 CHF to 170.10 CHF.
What Is Galderma (GALD) Price Target According to Analysts?
The average 12-month price target for Galderma is 177.11 CHF, with a high estimate of 252.70946681 CHF and a low estimate of 112.84392974 CHF. 11 analysts recommend buying the stock, while 1 suggest selling, leading to an overall rating of Buy. The stock has an +13.82% Upside potential.
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.